0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Sevelamer

      ,

      Nephron Clinical Practice

      S. Karger AG

      Sevelamer, Phosphate binders, Hyperphosphataemia

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hyperphosphataemia in patients with chronic renal failure has traditionally been treated with calcium- and aluminium-containing phosphate binders. This article briefly discusses the rationale and complications of these treatments and reviews sevelamer that is a novel non-calcium-, non-aluminium-containing phosphate binder and the evidence to support its use in clinical practice.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: not found
          • Article: not found

          Dialysis therapy.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder.

              Bookmark

              Author and article information

              Journal
              NEC
              Nephron Clin Pract
              10.1159/issn.1660-2110
              Nephron Clinical Practice
              S. Karger AG
              1660-2110
              2003
              July 2003
              17 November 2004
              : 94
              : 3
              : c53-c58
              Affiliations
              Oxford Kidney Unit, Churchill Hospital, Oxford, UK
              Article
              72021 Nephron Clin Pract 2003;94:c53–c58
              10.1159/000072021
              12902631
              © 2003 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Figures: 1, Tables: 1, References: 20, Pages: 1
              Product
              Self URI (application/pdf): https://www.karger.com/Article/Pdf/72021
              Categories
              Minireview: Therapeutic Advances

              Cardiovascular Medicine, Nephrology

              Hyperphosphataemia, Phosphate binders, Sevelamer

              Comments

              Comment on this article